AbbVie (ABBV) Says MAVYRET Shows High Virologic Cure Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
November 13, 2018 11:31 AM
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic hepatitis C virus (HCV) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
